Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 2/20 | 0.44 |
| ▸ | CCR9 | P51686 | 7/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3529397 | 0.90 | LMNA (0.49) | CCR9MAPK1ALDH1A1MAPTLMNA | |
| SCHEMBL3527411 | 0.88 | KDM1A (0.40) | CCR2CCR9ACLYMAPK1MAPT | |
| SCHEMBL3529238 | 0.87 | ACLY (0.41) | CCR9HSD17B2ACLYALDH1A1MAPT | |
| SCHEMBL3525988 | 0.83 | TSHR (0.49) | MAPK1ALDH1A1MAPTLMNA | |
| SCHEMBL3524492 | 0.83 | ALDH1A1 (0.43) | MAPK1ALDH1A1MAPTLMNA | |
| SCHEMBL3529380 | 0.81 | PKM (0.48) | CCR9MAPK1ALDH1A1MAPTLMNA | |
| SCHEMBL3523854 | 0.81 | ALDH1A1 (0.43) | CCR9ALDH1A1MAPTLMNA | |
| SCHEMBL3523501 | 0.81 | CCR2 (0.47) | CCR2CCR9ACLYMAPK1ALDH1A1 | |
| SCHEMBL3528038 | 0.81 | LMNA (0.46) | MAPK1ALDH1A1MAPTLMNA | |
| SCHEMBL3527218 | 0.81 | ALDH1A1 (0.43) | CCR9MAPK1ALDH1A1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436040-B2 | Method of treating conditions involving PPAR-receptors with indole compounds | LABORATOIRES FOURNIER S.A. (FR) | 2013-05-07 | — | — | US | disclosed |
| US-20100286137-A1 | Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds | LABORATORIES FOURNIER S.A. (FR) | 2010-11-11 | — | — | US | disclosed |
| US-7795297-B2 | Indole compounds, method of preparing them and uses thereof | LABORATORIES FOURNIER S.A. (FR) | 2010-09-14 | — | — | US | disclosed |
| US-20080153816-A1 | Indole Compounds, Method of Preparing Them and Uses Thereof | LABORATOIRES FOURNIER S.A. (FR) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153816-A1 | Indole Compounds, Method of Preparing Them and Uses Thereof | LIPG, GPR119, IAPP | CCR2 1853/4885CCR9 2577/4885HSD17B2 227/4885 |
| US-20100286137-A1 | Method of Treating Conditions Involving PPAR-Receptors with Indole Compounds | GPR119, PPARA, PPARG | CCR2 875/4885CCR9 2408/4885HSD17B2 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.